Combat obesity with data-driven medicine. We predict how YOU will respond to different weight loss interventions through biological samples, patient assessments, and machine learning.
Obesity affects roughly 42 percent of the American population, is a precursor to a wide range of chronic conditions and accounts for roughly $480 billion in healthcare spending each year.
Initial blood test for response to new weight loss drugs (like Wegovy) due to be launched early 2023
The Mayo Clinic and Phenomix Sciences are partnering on a biobanking registry aimed at collecting data from patients dealing with obesity and a national study to monitor phenotypes in patients undergoing treatments for obesity.
Experts say the project should offer new insights into how obesity is caused and how it may be treated.
Initial investment by Health 2047 (AMA and United Health)
Menlo Park, CA and St Paul, MN